antidepressants

shutterstock_129836540

Introduction

Antidepressants are medications used in the treatment of depression, but many can also be used in conditions such as anxiety disorders and obsessive compulsive disorder. Most antidepressants are taken orally.

What we already know

Antidepressants can be divided into six groups, based on their mechanism of action:

  1. Selective Serotonin Reuptake Inhibitors (SSRIs)“ e.g. Citalopram, Sertraline
  2. Serotonin-Noradrenaline Reuptake Inhibitors (SNRIs)“ e.g. Venlafaxine, Duloxetine
  3. Noradrenergic and Specific Serotonergic Antidepressants (NaSSAs) e.g. Mirtazapine
  4. Tricyclic Antidepressants (TCAs)“ e.g. Amitriptyline, Imipramine
  5. Monoamine Oxidase Inhibitors (MAO-Is) e.g. Phenelzine, Moclobemide
  6. Miscellaneous“ e.g. Bupropion, Trazodone, Reboxetine

Side effects depend on the mechanism of action and can vary from person to person.

NICE guidelines suggest use of antidepressants in moderate or severe cases of depression only. The risks of antidepressant medication use in mild depression outweigh the benefits, so other forms of therapy (e.g. CBT) are recommended in these cases.

Areas of uncertainty

  • The exact mechanisms of action – we are yet to find out exactly why and how many of the antidepressants work (there are inconsistencies in the monoamine theory of depression)
  • How to limit side effects associated with antidepressant use
  • How many people experience withdrawal effects and how best to withdraw from antidepressants
  • Using antidepressants in special groups – limited data exists for which antidepressants (if any) are best to use in pregnant women, children and the elderly

What’s in the pipeline

  • Ketamine has been shown to have promising antidepressant effects, although further randomised placebo-controlled trials are needed (Coyle and Laws, 2015)
  • Research is ongoing into the biological causes of depression and it is hoped that when this is better understood, therapy can be targeted towards the exact cause
  • Further research is also being conducted into the long term effects of antidepressants
  • Research aimed at developing more personalised treatment for depression is also underway

References

NICE guidelines CG90 (2009) ‘Depression in adults: The treatment and management of depression in adults’ [PDF]

Semple, D. and Smyth, R. (eds.) (2013) Oxford Handbook of Psychiatry. 3rd ed. Oxford: Oxford University Press. (Publisher)

Coyle, C. M. and Laws, K. R. (2015), ‘The use of ketamine as an antidepressant: a systematic review and meta-analysis.’ Hum. Psychopharmacol Clin Exp, doi: 10.1002/hup.2475 [Abstract]

Acknowledgement

Written by: Josephine Neale
Reviewed by: Helge Hasselmann
Last updated: Jun 2019
Review due: Jun 2020

Our antidepressants Blogs

The latest evidence from NICE on depression in children and young people

Young boy on roundabout

The NICE guideline for depression in children and young people was published way back in September 2005.  Any elf worth his salt will tell you that a whole heap of evidence has been published since then, so it’s good to see an evidence update appear this week from NICE, which brings together research published from 17th [read the full story…]

SSRIs and TCAs are equally effective at treating chronic depression, but SSRIs have fewer side effects

Tightrope walker

Major depression all too often develops a chronic course, with every episode making future relapse more likely (Gilmer et al., 2005). Dysthymic disorders represent a less severe, but more persistent form of depression lasting for at least two years. In the affective disorder spectrum, chronic forms are unsurprisingly associated with greater functional impairment and overall [read the full story…]

NICE publish first clinical guideline on social anxiety disorder

Social humiliation

I wonder if the timing of this publication was planned to be so close to the release of DSM-5, but this debut guidance on social phobia (now known as social anxiety disorder) is certainly going to ruffle some feathers. It fuels the discussion about the medicalisation of human personality traits and some will see it [read the full story…]

New guideline says lithium still appears to have the most robust evidence base as a long-term treatment for bipolar disorder

Bipolar

Bipolar disorder features as one of the top ten disabling disorders for working age adults. There are numerous risks including suicide, increased mortality and reduced social functioning associated with the disorder. Key to enabling recovery is preventing acute episodes from occurring, with each episode increasing the risk of future ones. Therefore ensuring long-term maintenance treatment [read the full story…]

CBT is better than nothing for older adults with depression, but so is any form of active support

Old man stretching

Depression is such a widely known issue now that it barely needs introduction. It’s something we Elves have covered with interest, looking at the effectiveness of various treatments, like psychotherapy, medication and exercise. For older adults though, there remains a somewhat hazy picture of what treatments work best. Most of the evidence base for the [read the full story…]

New RCT says antidepressants should not be used when treating depression in dementia

Senior woman taking pill

Dementia is one of the most common and serious disorders in later life. It places a considerable burden on the health care system, individuals and especially unpaid carers. Depression is common among people with dementia and causes additional distress to affected individuals and their social circle. Research into the treatment of depression in dementia is [read the full story…]

Atypical antipsychotics don’t improve quality of life in treatment-resistant depression

Hand holding pill

SSRIs are usually considered first-line treatment against major depression and approximately 50% of patients achieve remission with the drug they try first (Steffens, Krishnan, & Helms, 1997). However, every eighth case proves to be treatment-resistant and does not respond to standard antidepressant treatment at all. As a last resort, second-generation antipsychotics (SGAs) effective in schizophreniform [read the full story…]

Meta-analysis shows a small increased risk of brain haemorrhage in people taking SSRIs

Bleeding brain

Depression is a serious mental health threat proclaimed to be the greatest disease burden in the industrialised world by 2020 (Simon, 2003). In the pharmaceutical combat against depression, selective serotonin reuptake inhibitors (SSRIs) are the current treatment of choice. Indeed, SSRIs are the most prescribed antidepressant medicine (Helms & Eric, 2006). As the name suggests, they increase [read the full story…]

Cochrane review finds bupropion is the best treatment to help people with schizophrenia give up smoking

Woman breaking cigarette

People with schizophrenia are 2-3 times more likely to smoke tobacco than the rest of the population, so helping them quit is a significant public health issue. The evidence for smoking cessation interventions in the general population is fairly well defined. We know quite a bit about what works and we have a range of [read the full story…]

SSRI use in pregnancy does not increase the risk of stillbirth, neonatal mortality or post-neonatal mortality

Newborn baby and mother

Studies have shown that the prevalence of depression in pregnant women is 7-19%. Being depressed during pregnancy can result in preterm delivery, which can in turn lead to illness and even death of the newborn child. Researchers have struggled to single out the causes of these risks. Is it the depression, the medical treatment being [read the full story…]